Open Access<p>Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide</p>
Author(s) -
Wing Chow,
Prina Donga,
Aurélie Côté-Sergent,
Carmine Rossi,
Patrick Lefèbvre,
Marie-Hélène Lafeuille,
Hélène Hardy,
Bruno Émond
Publication year - 2020
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s272211
Subject(s) - darunavir , cobicistat , tenofovir alafenamide , medicine , emtricitabine , human immunodeficiency virus (hiv) , tenofovir , rilpivirine , pharmacology , virology , antiretroviral therapy , viral load
Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide can be used as a single-tablet regimen (STR, DRV/c/FTC/TAF) or multiple-tablet regimen (MTR, DRV/c+FTC/TAF) to treat patients with human immunodeficiency virus (HIV). This study described treatment patterns and predictors of adherence among patients with HIV initiated on DRV/c/FTC/TAF or DRV/c+FTC/TAF.